12 completed, 2 terminated, 2 withdrawn, 1 active not recruiting. 9 Phase 3, 8 Phase 2, 4 Phase 1.
By phase and status
Follow olokizumab: new trials by email Literature Review of olokizumab trials Research Report on olokizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease Placebo, Goflikicept, Olokizumab - Still Disease | Phase 3 | Not yet recruiting | 52 | 2026-05-18 | 2026-06-04 |
Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE) Olokizumab, Placebo - Polymyalgia Rheumatica | Phase 3 | Active not recruiting | 125 | 2025-06-11 | 2026-06-30 |
Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4 Olokizumab, Omeprazole, Caffeine - Rheumatoid Arthritis | Phase 1 | Completed | 17 | 2021-11-16 | 2024-08-15 |
Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection Olokizumab, Standard therapy - COVID-19 | | Completed | 3087 | 2021-07-14 | 2023-01-20 |
Study of Efficacy of Different Treatment Regimens of Olokizumab Olokizumab, Standard therapy - COVID-19 | Phase 3 | Unknown | 198 | 2021-07-08 | 2023-02-13 |
Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). Olokizumab 64 mg, Placebo - COVID-19 | Phase 2 / Phase 3 | Withdrawn | | 2020-06-30 | 2021-11-08 |
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19) RPH-104 80 mg, Olokizumab 64 mg, Placebo - COVID-19 | Phase 2 / Phase 3 | Completed | 372 | 2020-04-23 | 2022-01-24 |
Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Olokizumab 64 mg SC q4w, Olokizumab 64 mg SC q2w, Concomitant treatment - Rheumatoid Arthritis | Phase 3 | Completed | 2106 | 2017-07-04 | 2023-10-12 |
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease Olokizumab, Placebo - Rheumatoid Arthritis | Phase 3 | Completed | 368 | 2017-01-25 | 2023-09-21 |
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w - Rheumatoid Arthritis | Phase 3 | Completed | 1648 | 2016-06-06 | 2023-09-21 |
Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease Olokizumab, Placebo - Rheumatoid Arthritis | Phase 3 | Completed | 428 | 2016-05-19 | 2023-09-21 |
A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease Olokizumab (OKZ), Placebo - Crohn's Disease | Phase 2 | Withdrawn | | 2012-06-01 | 2012-10-30 |
The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis CDP6038 (olokizumab) - Rheumatoid Arthritis | Phase 2 | Terminated | 103 | 2012-01-26 | 2022-05-20 |
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy Placebo, Olokizumab 60 mg, Olokizumab 120 mg - Rheumatoid Arthritis | Phase 2 | Completed | 119 | 2011-10-01 | 2013-03-25 |
Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056 CDP6038 (olokizumab) - Rheumatoid Arthritis | Phase 2 | Terminated | 190 | 2011-03-07 | 2022-04-14 |
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy CDP6038, Tocilizumab (Actemra or RoActemra), Placebo sc - Rheumatoid Arthritis | Phase 2 | Completed | 221 | 2010-11-01 | 2024-07-17 |
Pharmacokinetic (PK)/Pharmacodynamic (PD), Study of Single-dose Subcutaneous CDP6038 in Healthy Japanese Male Subjects CDP6038, Placebo - Healthy Volunteers | Phase 1 | Completed | 20 | 2010-11-01 | 2011-09-27 |
To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate CDP6038, Placebo IV, Placebo SC - Arthritis, Rheumatoid Arthritis | Phase 1 / Phase 2 | Completed | 40 | 2009-10-01 | 2024-11-15 |
The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males CDP6038, Placebo - Pharmacokinetics | Phase 1 | Completed | 67 | 2008-09-01 | 2012-03-22 |
Conditions studied
Arthritis, Rheumatoid (10) · COVID-19 (4) · Coronavirus Infections (3) · Lung Diseases (2) · Respiration Disorders (2) · Arthritis (1) · Arthritis, Juvenile (1) · Crohn Disease (1) · Lymphoma, Follicular (1) · Polymyalgia Rheumatica (1)
Sponsors
R-Pharm International, LLC (8) · UCB Pharma (4) · R-Pharm (3) · UCB BIOSCIENCES, Inc. (2) · UCB BIOSCIENCES GmbH (1) · UCB Japan Co. Ltd. (1)
Countries
Russia (9) · United States (6) · Germany (5) · South Korea (5) · United Kingdom (5) · Bulgaria (4) · Taiwan (4) · Argentina (3) · Brazil (3) · Colombia (3) · Czechia (3) · Hungary (3) · Mexico (3) · Poland (3) · Belarus (2)
Top investigators
Mikhail Samsonov (11) · Mark Genovese, Dr (1) · Tsutomu Takeuchi, Professor (1)
Results publications
PMID 42142212, PMID 24641941, PMID 26358841, PMID 34344706, PMID 36001712, PMID 36109142, PMID 41239458
NIH funding
2015 (2), 2009 (1), 2014 (1)